

### Dermatology Referral Form

| PATIENT INFORMATION  |                               |                                 |
|----------------------|-------------------------------|---------------------------------|
| Patient Name _____   |                               |                                 |
| Address _____        |                               |                                 |
| City _____           | State _____                   | ZIP _____                       |
| Home Phone _____     | Cell _____                    |                                 |
| DOB _____            | SSN _____                     |                                 |
| Drug Allergies _____ | <input type="checkbox"/> Male | <input type="checkbox"/> Female |

| PRESCRIBER INFORMATION |              |           |
|------------------------|--------------|-----------|
| Prescriber Name _____  | DEA _____    |           |
| NPI# _____             | Tax ID _____ |           |
| Practice Name _____    |              |           |
| Address _____          | Suite _____  |           |
| City _____             | State _____  | ZIP _____ |
| Office Phone _____     | Fax _____    |           |

### COMPLETE OR FAX FRONT AND BACK COPIES OF INSURANCE, PRESCRIPTION AND/OR CO-PAY ASSISTANCE CARDS

|                                      |  |
|--------------------------------------|--|
| Primary Prescription Insurance _____ | Secondary Prescription Insurance (if applicable) _____ |
| Insurance Phone _____                | Insurance Phone _____                                  |

### CLINICAL INFORMATION - (PLEASE ATTACH A LIST OF PATIENTS'S CURRENT MEDICATIONS.)

Diagnosis  L40 Psoriasis  L40.52 Psoriasis Arthritis  L73.2 Hidradenitis (HS)  Other \_\_\_\_\_ Location of psoriasis:  Hands  Feet  Scalp  Groin  Nails  Other

Severity of psoriasis:  Mild (up to 3% BSA)  Moderate (3-10% BSA)  Severe (>10% BSA) BSA \_\_\_\_\_ % Previously treated for this condition?  Yes  No

Medication/Therapy:  Topical \_\_\_\_\_  Other \_\_\_\_\_

Is patient currently on therapy?  Yes  No Type/medication(s): \_\_\_\_\_ Patient tested for TB/PPD?  Yes  No Results: \_\_\_\_\_

Will patient stop the above medication(s) before starting the new medication?  Yes  No If yes, how long before starting the new medication?: \_\_\_\_\_

| DRUG NAME                      | PRESCRIPTION ORDERS (PLEASE CHECK ONE OR MORE)  | QTY   | REFILLS       |    |
|--------------------------------|---|---|---------------|----|
| Cimzia®                        | <input type="checkbox"/> 200mg Prefilled syringe  | <input type="checkbox"/> Inject 400mg subcutaneously every other week   | 2             |    |
|                                | <b>Option for &lt; 90kg:</b><br><input type="checkbox"/> Induction: Inject 400mg subcutaneously on day 1, week 2 and week 4<br><input type="checkbox"/> Maintenance: Inject 200mg subcutaneously every other week |   | 1 kit         | 0  |
|                                |   |   | 1             |    |
| Cosentyx® Limited Distribution | <input type="checkbox"/> 150mg Senoready Pen  | <input type="checkbox"/> Induction: Inject 300 mg subcutaneously at Weeks 0, 1, 2, 3.   | 28 Day Supply | 0  |
|                                | <input type="checkbox"/> 150mg Prefilled syringe  | <input type="checkbox"/> Maintenance: Inject 300mg subcutaneously every 4 weeks starting at week 4.   | 28 Day Supply |    |
| Dupixent®                      | <input type="checkbox"/> 300mg Prefilled syringe  | <input type="checkbox"/> Induction: Inject 600mg (2 syringes) subcutaneously on day 1, begin maintenance on day 15.<br><input type="checkbox"/> Maintenance: Inject 300mg subcutaneously every other week | 14 Day Supply | 0  |
|                                |   |   | 28 Day Supply |    |
| Enbrel®                        | <input type="checkbox"/> 50mg Sureclick   | <input type="checkbox"/> Induction: Inject 50mg subcutaneously twice weekly for three months then maintenance dose  | 84 Day Supply | 0  |
|                                | <input type="checkbox"/> 50mg Prefilled syringe   | <input type="checkbox"/> Maintenance: Inject 50mg subcutaneously weekly   | 28 Day Supply |    |
| Enbrel®                        | <input type="checkbox"/> Mini   | <input type="checkbox"/> Other _____  |               |    |
|                                | <input type="checkbox"/> 25mg Vial kit  | <input type="checkbox"/> Inject 25mg subcutaneously twice weekly  | 28 Day Supply |    |
| Humira®-Citrae Free            | <input type="checkbox"/> 40mg Pen   | <input type="checkbox"/> Psoriasis Induction: Inject 80mg subcutaneously on day 1, followed by 40mg every other week starting on day 8  | 1 starter kit | 0  |
|                                | <input type="checkbox"/> 40mg Prefilled syringe   | <input type="checkbox"/> Psoriasis Maintenance: Inject 40mg subcutaneously every other week   | 28 Day Supply |    |
|                                | <input type="checkbox"/> HS Induction: Inject 160mg subcutaneously on day 1, then 80mg on day 15, maintenance dose on day 29  |   | 1 starter kit | 0  |
|                                | <input type="checkbox"/> HS Maintenance: Inject 40mg subcutaneously every week  |   | 28 Day Supply |    |
| Ilumya®                        | <input type="checkbox"/> 100mg Prefilled Syringe  | <input type="checkbox"/> Induction: Inject 100mg under the skin at week 0 and 4, then every 12 weeks thereafter   | 28 Day Supply | 0  |
|                                | <input type="checkbox"/> Maintenance: Inject 100mg under the skin every 12 weeks  |   | 84 Day Supply |    |
| Otezla®                        | <input type="checkbox"/> 28 Day Starter Pack  | <input type="checkbox"/> Induction: Take per package directions   | 28 Day Supply | 0  |
| Otezla®                        | <input type="checkbox"/> 30mg tablets   | <input type="checkbox"/> Maintenance: Take 30mg by mouth twice a day.   | 30 Day Supply |    |
|                                | <input type="checkbox"/> Bridge: Take 30mg by mouth twice a day, dispensed by OSP Titration date _____  |   | 14 Day Supply | 12 |
| Siliq®                         | <input type="checkbox"/> 210mg Prefilled Syringe  | <input type="checkbox"/> Induction: Inject 210mg under the skin at week 0, and 1  | 14 Day Supply | 0  |
|                                | <input type="checkbox"/> Maintenance: Inject 210mg under the sk-in every 2 weeks starting at day 15   |   | 28 Day Supply |    |
| Skyriz®                        | <input type="checkbox"/> 75mg Prefilled syringe   | <input type="checkbox"/> Inject 150mg (2 syringes) under the skin at Week 0, week 4, and every 12 weeks thereafter  | 2             |    |
| Stelara®                       | <input type="checkbox"/> 45mg Prefilled syringe   | <input type="checkbox"/> < 100kg Body Weight: Inject 45mg subcutaneously on Day 1, again after 4 weeks, then every 12 weeks after.  | 28 Day Supply | 0  |
|                                | <input type="checkbox"/> 90mg Prefilled syringe   | <input type="checkbox"/> >100kg Body Weight: Inject 90mg subcutaneously on Day 1, again after 4 weeks, then every 12 weeks after.   | 84 Day Supply |    |
| Taltz®                         | <input type="checkbox"/> 80mg Prefilled syringe   | <input type="checkbox"/> Starting Dose: Inject under the skin two 80 mg injections on Day 1.  | 2             | 0  |
|                                | <input type="checkbox"/> 80mg Pen   | <input type="checkbox"/> Starting Dose w/ Induction: Inject under the skin two 80 mg injections on Day 1, then begin first induction dose 2 weeks later.  | 3             | 0  |
|                                | <input type="checkbox"/> Induction Dose: Inject under the skin one 80 mg injection every 2 weeks (weeks 4-10)   |   | 2             | 1  |
|                                | <input type="checkbox"/> Final Induction Dose: Inject under the skin one 80 mg injection (week 12).   |   | 1             | 0  |
|                                | <input type="checkbox"/> Maintenance Dose: Inject under the skin one 80 mg injection every 4 weeks.   |   | 1             |    |
| Tremfya®                       | <input type="checkbox"/> 100mg Prefilled Syringe  | <input type="checkbox"/> Induction: Inject 100mg under the skin at week 0, then begin maintenance at week 4.  | 28 Day Supply | 0  |
|                                | <input type="checkbox"/> 100mg Pen  | <input type="checkbox"/> Maintenance: Inject 100mg under the skin every 8 weeks.  | 56 Day Supply |    |

Deliver to:  Patient's Home  
 Physician's Office  
 1st dose to MD's Office, remaining refills to patient's home

Training:  Patient has received injection training  
 Physician's office to provide injection training  
 Pharmacy to coordinate injection training

Prescriber's Signature (signature required. NO STAMPS) \_\_\_\_\_ Date \_\_\_\_\_

By signing this form and utilizing our services, you are authorizing Benevere and it's employees to serve as your prior authorization designated agent in dealing with medical and prescription insurance companies.

IMPORTANT NOTICE: This fax is intended to be delivered only to the named addressee. It contains material that is confidential, privileged, proprietary or exempt from disclosure under applicable law. If you are not the named addressee, you should not disseminate, distribute or copy this fax. Please notify the sender immediately if you have received this document in error and then destroy this document immediately.